Generated Narrative: CodeSystem ssf-2-leukemia-codesystem This case-sensitive code system https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem defines the following codes: Code Display 000 正常 001 AML with RUNX1-RUNX1T1 002 AML with CBFB-MYH11 003 Acute promyelocytic leukemia with PML-RARA 004 AML with KMT2A-MLLT3 005 AML with DEK-NUP214 006 AML with GATA2, MECOM 007 AML(megakaryoblastic) with RBM15-MKL1 008 AML with mutated NPM1 009 AML with biallelic mutation of CEBPA 010 AML with mutated FLT3/ITD 011 AML with mutated FLT3/TKD 012 AML with MLL-PTD (partial tandem duplication) 013 AML with BCR-ABL1 021 B lymphoblastic leukemia/lymphoma with BCR-ABL1 022 B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged 023 B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1) 024 B-lymphoblastic leukemia/lymphoma with IGH/IL3 025 B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1) 041 Mixed phenotype acute leukemia with BCR-ABL1 042 Mixed-phenotype acute leukemia with KMT2A-rearranged 051 Chronic myelogenous leukemia BCR-ABL1 positive 052 JAK2 V617F mutation 053 Myeloid and lymphoid neoplasms with PDGFRA rearrangement 054 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 055 Myeloid and lymphoid neoplasms with FGFR1 rearrangement 090 (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常 091 同時有兩種(含)以上上述之分子檢驗異常 092 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常 8XX Molecular study after chemotherapy or immunotherapy or target therapy 988 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4) 998 有執行分子生物學檢查，但結果無法判斷 999 (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查
SSF2 白血病-白血病分子生物學檢查的評估代碼系統
Assessment of molecular studies in leukemia Code System
Acute promyelocytic leukemia with PML-RARA
AML with MLL-PTD (partial tandem duplication)
B lymphoblastic leukemia/lymphoma with BCR-ABL1
B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged
B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)
B-lymphoblastic leukemia/lymphoma with IGH/IL3
B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)
Mixed phenotype acute leukemia with BCR-ABL1
Mixed-phenotype acute leukemia with KMT2A-rearranged
Chronic myelogenous leukemia BCR-ABL1 positive
Myeloid and lymphoid neoplasms with PDGFRA rearrangement
Myeloid and lymphoid neoplasms with PDGFRB rearrangement
Myeloid and lymphoid neoplasms with FGFR1 rearrangement
(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常
同時有兩種(含)以上上述之分子檢驗異常
同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常
Molecular study after chemotherapy or immunotherapy or target therapy
有執行分子生物學檢查，但結果無法判斷
(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查